Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

ClinicalTrials.gov ID: NCT02770170

Public ClinicalTrials.gov record NCT02770170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Study identification

NCT ID
NCT02770170
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
121 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 16, 2016 (Actual)
Primary completion
Jun 23, 2020 (Actual)
Completion
Aug 18, 2020 (Actual)
Last update posted
Oct 16, 2025

2016 – 2020

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
Academic Medical Research Institute Los Angeles California 90022 —
Integrity Clinical Research, LLC Doral Florida 33166 —
Hope Clinical Research Kissimmee Florida 34741 —
Integral Rheumatology and Immunology Specialist Plantation Florida 33324 —
Emory University Atlanta Georgia 30322 —
Northwell Health Great Neck New York 11021 —
Feinstein Institute for Medical Research Manhasset New York 11030 —
Columbia University Medical Center-New York Presbyterian Hospital New York New York 10032 —
Office of Dr. Ramesh C. Gupta Memphis Tennessee 38119 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02770170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 16, 2025 · Synced Oct 31, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02770170 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →